Stefan Lethagen (Former)
1 – 50 of 77
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
(
- Contribution to journal › Article
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
- 2021
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2018
-
Mark
Genetic Variation in the Syntaxin-Binding Protein STXBP5 in Type 1 von Willebrand Disease Patients
(
- Contribution to journal › Article
-
Mark
Genetic variation in the C-type lectin receptor CLEC4M in type 1 von Willebrand Disease patients
(
- Contribution to journal › Article
- 2017
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
- 2011
-
Mark
A large deletion identified in a Swedish family with type 1 VWD
(
- Contribution to journal › Letter
-
Mark
Variation in the VWF Gene in Swedish Patients with Type 1 von Willebrand Disease.
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
- 2010
-
Mark
The impact of bleeding history, von Willebrand factor and PFA-100 (R) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD
(
- Contribution to journal › Article
-
Mark
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
(
- Contribution to journal › Article
- 2008
-
Mark
Asn1421Lys mutation in the glycoprotein Ib binding domain impairs - ristocetin and botrocetin - mediated binding of von Willebrand factor to platelets
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
Distribution of von Willebrand factor levels in young women with and without bleeding symptoms. Influence of ABO blood group and promoter haplotypes
(
- Contribution to journal › Article
-
Mark
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)
(
- Contribution to journal › Article
-
Mark
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
(
- Contribution to journal › Article
-
Mark
Patients' and their family members' understanding of the genetics of type 1 von Willebrand disease.
(
- Contribution to journal › Letter
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
(
- Contribution to journal › Article
-
Mark
Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD)
(
- Contribution to journal › Article
-
Mark
Von Willebrand factor/factor VIII concentrate (Haemate(R) P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
(
- Contribution to journal › Article
-
Mark
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)
(
- Contribution to journal › Article
-
Mark
Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
(
- Contribution to journal › Article
- 2006
-
Mark
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)
(
- Contribution to journal › Article
-
Mark
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study
(
- Contribution to journal › Article
-
Mark
Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity.
(
- Contribution to journal › Article
-
Mark
Prothrombin deficiency caused by compound heterozygosity for two novel mutations in the prothrombin gene associated with a bleeding tendency
(
- Contribution to journal › Article
-
Mark
Bleeding disorders among young women: a population-based prevalence study.
(
- Contribution to journal › Article
-
Mark
Factors influencing factor VIII activity in frozen plasma.
(
- Contribution to journal › Article
- 2005
-
Mark
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study
(
- Contribution to journal › Article
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype.
(
- Contribution to journal › Article
- 2004
-
Mark
A comparative in vitro evaluation of six von Willebrand factor concentrates.
(
- Contribution to journal › Article
-
Mark
Economic evaluation: what are we looking for and how do we get there?
(
- Contribution to journal › Article
-
Mark
Co-segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1.
(
- Contribution to journal › Article
-
Mark
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
(
- Contribution to journal › Article
- 2003
-
Mark
Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke?
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure.
(
- Contribution to journal › Article
-
Mark
Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity.
(
- Contribution to journal › Letter
-
Mark
Experience with a new percutaneous port system, Percuseal(R), for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.
(
- Contribution to journal › Article
-
Mark
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
(
- Contribution to journal › Article
-
Mark
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
(
- Contribution to journal › Article
-
Mark
Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
(
- Contribution to journal › Article
- 2002
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Von Willebrand's disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X).
(
- Contribution to journal › Article
- 2001
-
Mark
Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome
(
- Contribution to journal › Article
-
Mark
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(
- Contribution to journal › Article